Related Experiment Video
Updated: Jun 5, 2026

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse
Published on: November 10, 2008
Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned?
1Protein Studies Program, Oklahoma Medical Research Foundation, University of Oklahoma Health Science Center, Oklahoma City, USA. Jordan‐Tang@omrf.org
Abstract:
β-Secretase is an attractive target of amyloid-reduction therapy for Alzheimer's disease. Currently, no efficacy data is available from clinical trials of β-secretase inhibitors. Treating young transgenic Tg2576 mice with a brain-penetrating β-secretase inhibitor reduced brain amyloid-β by about 50% and rescued the age-related cognitive decline. Implications from these model studies on the design of clinical trials are discussed herein.
More Related Videos
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017